Bicyclic peptides are synthetic, highly constrained peptides, typically between 9 and 15 amino acids in size.
Bicyclic peptides are highly soluble and provide manufacturing and formulation flexibility. Increased conformational rigidity of bicyclic peptides is obtained by tying the peptide up on small central molecular scaffolds, which results in molecules with high target specificity and affinity resembling antibodies or small proteins. Bicyclic peptides can be used as therapeutics against a diverse set of targets but also as targeting ligands similar to the antibody part of an antibody-drug conjugate. Bicyclic peptides are also proteolytically stable with improved plasma stability compared to linear peptides. This means they have “tuneable” pharmacokinetics and are cleared by the kidney.
AstraZeneca is one of the world’s most exciting bio-pharmaceutical companies. Be inspired by the possibilities of science to make a difference and discover what you can do.
Partner with us
We know that innovation doesn’t happen in isolation, so we partner with others to access the best science and contribute complementary technologies, know-how and molecules.
Learn about us
Our IMED Biotech unit is committed to driving scientific advances in small molecules, oligonucleotides and other emerging technology platforms to push the boundaries of medical science.